JG
ANIK icon

Jefferies Group’s Anika Therapeutics ANIK Stock Holding History

Jefferies Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-74,000
Closed -$2.24M – 2492
2019
Q1 		$2.24M Buy
+74,000
New +$2.53M 0.02% 859
2018
Q4 		– Sell
-13,800
Closed -$582K – 2138
2018
Q3 		$582K Hold
13,800
– – ﹤0.01% 1567
2018
Q2 		$442K Buy
+13,800
New +$568K ﹤0.01% 1659

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Jefferies Group's ANIK Position: Q3 2020 in Review

Jefferies Group sold out of Anika Therapeutics (ANIK) in Q3 2020, closing a stake of 50,615 shares — an estimated $1.91K sold.

Jefferies Group first reported a position in ANIK in Q2 2014 and held it in 10 quarters. The position peaked at $2.75M in Q1 2019. 156 funds tracked by Wall St. Rank hold ANIK as of Q3 2020.

  • Jefferies Group reported no remaining Anika Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 50,615 Anika Therapeutics shares in Q3 2020, an estimated $1.91K.
  • Jefferies Group first reported a position in Anika Therapeutics in Q2 2014 and held it in 10 quarters.
  • Jefferies Group's Anika Therapeutics position peaked at $2.75M in Q1 2019.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.